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Abstract
Background: Integrin-targeting radiopharmaceuticals have potential broad applications, spanning from cancer
theranostics to cardiovascular diseases. We have previously reported preclinical dosimetry results of 68Ga-NODAGA-
RGDyK in mice. This study presents the first human dosimetry of 68Ga-NODAGA-RGDyK in the five consecutive
patients included in a clinical imaging protocol of carotid atherosclerotic plaques. Five male patients underwent
whole-body time-of-flight (TOF) PET/CT scans 10, 60 and 120 min after tracer injection (200 MBq). Quantification of
68Ga activity concentration was first validated by a phantom study. To be used as input in OLINDA/EXM, time-
activity curves were derived from manually drawn regions of interest over the following organs: brain, thyroid,
lungs, heart, liver, spleen, stomach, kidneys, red marrow, pancreas, small intestine, colon, urinary bladder and whole
body. A separate dosimetric analysis was performed for the choroid plexuses. Female dosimetry was extrapolated
from male data. Effective doses (EDs) were estimated according to both ICRP60 and ICRP103 assuming 30-min and
1-h voiding cycles.
Results: The body regions receiving the highest dose were urinary bladder, kidneys and choroid plexuses. For a 30-
min voiding cycle, the EDs were 15.7 and 16.5 μSv/MBq according to ICRP60 and ICRP103, respectively. The
extrapolation to female dosimetry resulted in organ absorbed doses 17% higher than those of male patients, on
average.
The 1-h voiding cycle extrapolation resulted in EDs of 19.3 and 19.8 μSv/MBq according to ICRP60 and ICRP103,
respectively. A comparison is made with previous mouse dosimetry and with other human studies employing
different RGD-based radiopharmaceuticals.
Conclusions: According to ICRP60/ICRP103 recommendations, an injection of 200 MBq 68Ga-NODAGA-RGDyK leads
to an ED in man of 3.86/3.92 mSv. For future therapeutic applications, specific attention should be directed to
delivered dose to kidneys and potentially also to the choroid plexuses.
Trial registration: Clinical trial.gov, NCT01608516
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Background
The development of new blood vessels, namely neo-
angiogenesis, plays an essential role in many physiological
and pathological processes. In oncology, factors mediating
endothelial cell adhesion and migration (e.g. integrins), as
well as vascular growth factors, are associated with tumour
progression and development of metastases, and have be-
come the target of several anti-cancer compounds [1].
A specific marker of angiogenesis is the avβ3 integrin,
which is targeted with high affinity by the peptidic com-
pound arginine-glycine-aspartic acid (RGD). Several pro-
teins of the extracellular matrix like vitronectin, fibrinogen
and fibronectin interact with integrin ανβ3 via the RGD se-
quence [2].
A number of single photon (SPECT) and positron emit-
ting (PET) tracers for ανβ3 integrin have been developed
based on RGD cyclic sequences, such as RGDyK or
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RGDfK [3]. Among the PET tracers, 18F-Galacto-RGD has
been most extensively used but its synthesis has a low
radiochemical yield and requires almost two 18F half-lives,
on average [4]. Radiolabelling of generator-produced 68Ga
with either DOTA or NODAGA chelators allows for a
more efficient, faster and fully automated production [5–9].
Many of these integrin-targeting radiolabelled com-
pounds, initially developed for cancer theranostics, have
been later applied to cardiovascular diseases, showing
that neo-angiogenesis is a quantifiable process of cardiac
remodeling after an ischemic injury in animal models
[10–12] as well as in humans [13, 14].
Since integrin-mediated cell chemotaxis and angiogen-
esis represent a key feature of atherosclerotic plaque vul-
nerability [15], radionuclide imaging of ανβ3 can be
applied earlier in the ischemic process, potentially identi-
fying those vascular lesions carrying an increased risk of
complications [16–20].
Carotid artery disease is one of the leading causes of
morbidity and mortality worldwide and represents there-
fore a field of potential broad application for RGD-based
radionuclide probes [19, 20]. Indeed, newer risk models
for carotid plaque evaluation include the assessment of
vulnerability beyond the degree of luminal narrowing
[21–23].
We have previously reported preclinical dosimetry and
toxicity results of 68Ga-NODAGA-RGDyK in outbred fe-
male Hsd ICR (CD-1®) mice [24].
The aim of the present study was to assess the human
dosimetry of 68Ga-NODAGA-RGDyK in the first five pa-
tients included in a clinical research protocol applying
multimodality imaging to carotid atherosclerotic plaques
before endarterectomy.
Methods
Patients
The present dosimetry sub-study was designed to in-
clude the first five consecutive patients enrolled in a
clinical study comparing 68Ga-NODAGA-RGDyK PET/
CT, 18F-fluorodeoxyglucose (FDG) PET/CT, magnetic
resonance and ultrasound against histology in the assess-
ment of carotid plaque vulnerability. Patients were in-
cluded if presenting with any of the following: (i)
symptomatic carotid stenosis of any degree or (ii)
asymptomatic stenosis >70%.
Contraindications to surgery or gadolinium injection
represented exclusion criteria, together with pregnancy,
age >85, Karnofsky index <80% and inability to provide
written informed consent.
The study was authorized by the Ethical Committee of
Canton Vaud, Swissmedic and the Federal Office of Public
Health (FOPH). Patients gave separate written informed
consent to the clinical and the dosimetry protocol before
radiopharmaceutical administration.
Radiochemistry
The NODAGA-RGDyK is a GMP-produced monomeric
integrin-targeting peptide purchased from Advanced
Biochemical compounds ABX, Radeberg, Germany. As
previously described [24], the NODAGA-RGDyK was
radiolabelled with the 68Ga eluate of a 68Ge-generator
IGC100 (Eckert & Ziegler, Germany) using an automatic
processor unit, Modular-Lab PharmTracer (Eckert &
Ziegler, Germany). 68Ga was eluted with 0.1 mol/l HCl.
NODAGA-RGDyK (20 μg) was radiolabelled with the
high activity 68Ga fraction by incubation for 20 min at
room temperature. After cartridge purification, the ready
for use 68Ga-NODAGA-RGDyK was eluted in 50% etha-
nol through a 0.22-μm sterile filter and diluted into
NaCl solution. High-pressure liquid chromatography
analysis was performed on a μ-Bondapak column
(Waters C-18) run with trifluoroacetic acid and
acetonitrile.
PET/CT acquisition protocol
Three whole-body images (from top of the skull to mid
femora, 2 min/bed position) were acquired on a Discov-
ery 690 time of flight (TOF) PET/CT (GE Healthcare,
Milwaukee, Wisconsin, USA) [25] 10 ± 2, 60 ± 5 and
120 ± 5 min after the intravenous injection of 200 MBq
68Ga-NODAGA-RGDyK. Patients were asked to void
between scans (30-min voiding cycle). The list-mode
acquisition integrating TOF information and point-
spread-function recovery was reconstructed with a pro-
prietary three-dimension ordered subset expectation
maximization (3D-OSEM) algorithm (GE-VPFXS, 3 it-
erations × 16 subsets) including a FWHM= 5 mm
Gaussian post-reconstruction filter. All pertinent image
corrections (normalization, dead time, activity decay,
random coincidence, attenuation and scatter correc-
tions) were applied. The acquired field of view size was
70 cm reconstructed in a 256 × 256 image matrix. Re-
constructed voxel size was 2.73 × 2.73 mm in the trans-
verse plane and 3.27 mm in the axial direction.
Morphologic information was obtained from a whole-
body CT scan: 120 kVp, 60 mA, pitch = 3. The activity
concentration measured in each patient multi-bed ac-
quisition was decay corrected (physical decay correc-
tion) to the start of the PET acquisition.
Quantitative accuracy assessment
Quantitative accuracy was assessed in a NEMA NU2
phantom with the same acquisition and reconstruction
parameters used for patients. The phantom (volume
9340 cm3) was filled with 42.3 MBq of 68Ga in aqueous
solution measured at the image acquisition start time,
resulting in an activity concentration of 4.52 kBq/mL
which mimics the typical average activity concentration
present in patient organs. In 10 phantom background
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regions of 3 × 3 cm2, an average activity concentration of
4.25 kBq/mL was measured, which is 6% lower than the
actual value. Such discrepancy is compatible with the ac-
curacy of the well counter used for the 68Ga activity meas-
urement before filling the phantom.
Organ segmentation and dose estimations
Volumes of interest (VOI) were manually drawn slice by
slice on the axial plane of the CT part of every PET/CT
study using PMOD (PMOD Technologies, Zurich,
Switzerland) for the following body regions: brain, thy-
roid, lungs, heart, liver, spleen, stomach, kidneys, red
marrow, pancreas, small intestine, colon and whole
body. Choroid plexuses and urinary bladder were visu-
ally segmented on the emission PET data by two opera-
tors in consensus (SG and FC). CT-based segmentation
of choroid plexuses would have been challenging and, if
applied to bladder, it would have not taken into account
possible changes of volume due to bladder filling during
the PET/CT acquisition time.
As recommended by the MIRD pamphlet 16 for a
three-data point study [26], a mono-exponential fit ex-
tended to infinite beyond the last measured data point
was used to derive time-integrated activity coefficients
(TIAC) in each selected organ. The goodness of fit for
each organ was expressed by the R2 metric. Organ resi-
dence times were obtained by dividing TIAC for the ad-
ministered 68Ga total activity. For each patient, two red
marrow VOIs were drawn, the first in the heads of both
femora and the second in the lumbar vertebrae L3–L4.
The total number of disintegration which occurred in
the red marrow was obtained by averaging the number
of disintegration per unit of mass of these two regions
and then multiplying this value by the red marrow mass
of the OLINDA adult male reference phantom [27]. This
methodology is an extension to 3D images of the
method presented by Ferrer et al. [28]. The calculation
performed in two separate bone marrow regions, the
lumbar vertebrae (L3–L4) and the head of femora aimed
at reducing quantitative bias due to heterogeneity in red
marrow uptake [29]. Since no relevant heterogeneities of
activity distribution were observed in the colon tract, the
total number of disintegrations in this organ was parti-
tioned to its components (upper large intestine, lower
large intestine) proportionally to their respective masses
of the OLINDA male reference phantom. Organ resi-
dence times were used in input to the OLINDA/EXM
(Organ Level INternal Dose Assessment/EXponential
Modeling) code [30]. OLINDA/EXM provided organ
absorbed doses and effective dose (ED) per absorbed ac-
tivity in μGy/MBq and μSv/MBq, respectively, using the
ICRP60 tissue weighting factors [31]. The ED was also
re-evaluated manually from organ equivalent doses
adopting the tissue weighting factors recommended by
the ICRP103 [32]. The influence of a longer urinary
bladder voiding cycle (1 h) on dose estimations was also
assessed to facilitate the comparison with previous simi-
lar dosimetric studies of RGD-like radiopharmaceuticals
[33–37]
A specific dose assessment was performed for the
choroid plexuses, which do not appear in the list of
available organs in OLINDA. The residence time mea-
sured for this VOI was used as input in the OLINDA
sphere model. The mass of the body, atrial and temporal
part of the choroid plexuses in the lateral ventricles was
estimated assuming a cylindrical geometry based on
their length and width reported by Kuruoglu et al. for
both male and female subjects [38]. The masses of the
choroid plexuses were estimated to be 2.76 and 1.81 g
for male and female, respectively, which is close to the
mass of 2 g reported by others [39].
Having enrolled only male patients, the organ dose
and ED for female were extrapolated from male refer-
ence times applied to the organ masses of the OLINDA/
EXM adult female phantom, considering a voiding cycle
of 1 h. The ED for the reference person was computed
from the equivalent organ dose for male and female ac-
cording to the ICRP 103 methodology.
Results
Imaging
Five male patients (mean age 66, range 53–76 years),
were included. Three patients presented with symptoms
associated with carotid stenosis, the two remaining pa-
tients were asymptomatic. Patient characteristics, includ-
ing severity and site of carotid artery stenosis, are
reported in Table 1.
At the time of writing, definitive results of the main
clinical protocol are not available and will be reported
elsewhere. A preliminary comparison between 68Ga-
NODAGA-RGDyK and FDG PET/CT suggests a higher
rate of lesion detection for 68Ga-NODAGA-RGDyK,
with 3/5 sites of carotid stenosis showing increased up-
take values compared with the controlateral side. In con-
trast, FDG was unremarkable at the sites of known
stenosis. An increased FDG uptake was seen in the soft
tissues at the site of previous surgery in all the three pa-
tients who had undergone contralateral endarterectomy
2 to 12 months before the start of the current imaging
protocol.
Patient dosimetry
All injections were well-tolerated. No immediate symp-
toms or modification of vital signs were observed. At
first time point images, significant uptake was seen in
the urinary system. Mild uptake was also observed in the
thyroid gland, liver, spleen and intestine. The kidney ac-
tivity showed only a mild decrease over time, being still
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visible at the latest time point images. Figure 1 shows an
example of maximum intensity projection images ob-
tained 10, 60 and 120 min after tracer injection. A sig-
nificant uptake was observed in the choroid plexuses
since the early time point images, as already described
by others [35] (see Fig. 2). Time-activity curves for kid-
neys, liver, small intestine, spleen, red marrow and chor-
oidal plexuses are shown in Fig. 3.
The residence times, organ absorbed doses and ED
of the patients enrolled, as well as the extrapolated
values to female and reference person, are reported in
Table 2.
The standard organs receiving the highest absorbed dose
were the urinary bladder wall, the kidneys, and the small in-
testine (89.4, 46.3 and 30.1 μGy/MBq, respectively). The
measured absorbed dose in the choroid plexuses was 39.6
μGy/MBq in the male cohort and resulted to be 56.6 μGy/
MBq for the female extrapolation (see Table 3).
Organ time-activity curves corrected for 68Ga physical
decay are shown in Fig. 4.
For a 30-min voiding cycle, the EDs were 15.7 and
16.5 μSv/MBq according to ICRP60 and ICRP103,
respectively.
The extrapolation to female dosimetry resulted in
organ absorbed doses 17% higher than those of male pa-
tients, on average. For female patients, the extrapolated
EDs were 24.3 μSv/MBq and 22.5 μGy/MBq according
to ICRP60 and ICRP103, respectively (1-h voiding cycle).
The extrapolation to 1-h voiding cycle resulted in a
74% increase of the residence time in the urinary blad-
der. This resulted in a 23–24% ED increment for male
and female, respectively. Table 4 shows a dosimetry
comparison with previous studies on RDG-based PET
radiopharmaceuticals.
Discussion
Radiopharmaceuticals targeting integrins have a poten-
tial very broad field of application, spanning from cancer
theranostics to cardiovascular diseases. Several RGD
peptides have been tested over the recent past showing
that the number of RDG moieties, the isotope and the
chelator profoundly affect the synthetic process, binding
potential and in vivo biodistribution [3]. A clear advan-
tage of 68Ga-NOTA- or 68Ga-NODAGA RGD-based ra-
diopharmaceuticals is that they allow for a fast and fully
automated labelling at room temperature. Hence,
Table 1 Patient characteristics, including neurological symptoms and % stenosis, as measured by magnetic resonance imaging (MRI)
Patient ID Age (years) Body mass
index (kg/m2)
Symptoms (Y/N) Diagnosis (% stenosis)
1 62 30 N >80% right ICAa
2 53 23 Y 84% right ICA; 65% left ICA
3 65 26 Y 80% right ICAa
4 76 31 N >90% left ICA; >50% right ICA
5 72 21 Y >80% left ICAa
ICA internal carotid artery
aPatients who underwent previous contralateral endarterectomy
Fig. 1 From left to right, example of maximum intensity projections 10, 60 and 120 min post tracer injection showing 68Ga-NODAGA-RGDyK
uptake distribution in major abdominal organs. In this patient case, retention of radio-urine in the excretory system is exacerbated by
prostatic hypertrophy
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dosimetric studies are necessary as they might inform
the choice of the radiopharmaceutical, especially in view
of potential therapeutic applications [40, 41].
We had previously carried out a biodistribution study
of 68Ga-NODAGA-RGDyK in mice where projected hu-
man doses were also calculated. In addition, this previ-
ous preclinical work included a tolerance test of
NODAGA-RGDyK, showing no toxicity at 1000-fold ex-
cess per kilogram of body weight compared with the
maximum amount of peptide injected in a 70-kg patient
[24]. In the present study, we provide the first in-human
dosimetry of 68Ga-NODAGA-RGDyK in five male pa-
tients scheduled to undergo carotid endarterectomy.
Similar-sized studies were carried out with two fluori-
nated compounds, the dimeric 18F-FPPRGD2 [33] and
the monomeric 18F-RGD-K5 [34] respectively, as well as
with the dimeric 68Ga-labelled DOTA-RGDfK [35]. Two
larger dosimetry studies, including 18 and 10 patients
Fig. 2 Typical uptake pattern in the choroid plexuses of the lateral ventricles. Left-hand site panel shows 68Ga-NODAGA-RGDyK absence of uptake
in the frontal horns of the lateral ventricles. The central and right-hand side panels show increased uptake in the occipital and temporal horns of
the lateral ventricles, while only faint uptake is seen in the plexus of the third ventricle
Fig. 3 68Ga-NODAGA-RGDyK time-activity concentrations for some of the most irradiated organs. The organ activity was normalized to the
injected activity and organ mass (%IA/g). Blue circles at each time point indicates the measurements for the five patients enrolled in this study.
Solid lines represent the mono-exponential fits and error bars indicate ±SD. The coefficient of determination (R2) of the fit is reported for
each organ
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each, were conducted with the monomeric 18F-Galacto-
RGD [37] and 68Ga-NOTA-RGD, respectively [36].
Consistently with most of the abovementioned stud-
ies, we also found the most irradiated organs to be
the urinary bladder wall and the kidneys; a prominent
dose was also given to the intestine, the spleen and
the liver.
Contrarily to Doss and co-authors [34], we could not
confirm the gallbladder as one of the most irradiated or-
gans, being the tracer uptake of the gallbladder not dif-
ferent from that of the surrounding liver parenchyma. In
addition, we did not find significant dose heterogeneity
between the intestinal segments, which is a clear differ-
ence with the results of Mittra et al. [33].
Table 2 Residence times, organ absorbed doses and EDs according ICRP60 and ICRP103 for 30-min and 1-h urinary voiding cycles
in men. Extrapolated organ dose in female and defence person is reported for 1-h urinary voiding cycle only
Patient cohort (n = 5 male) Female Reference
Residence time 0.5-h voiding 1-h voiding 1-h voiding
Target organ Mean
(hours)
SD Dose
(mGy/MBq)
SD Dose
(mGy/MBq)
SD Dose
(mGy/MBq)
Dose
(mGy/MBq)
Adrenals 6.40E−03 5.42E−04 6.42E−03 5.37E−04 8.18E−03 7.30E−03
Brain 3.20E−03 7.09E−04 1.77E−03 2.64E−04 1.77E−03 2.64E−04 2.15E−03 1.96E−03
Breasts 4.58E−03 2.99E−04 4.58E−03 2.96E−04 5.86E−03 5.22E−03
Gallbladder wall 7.01E−03 6.41E−04 7.07E−03 6.44E−04 8.69E−03 7.88E−03
LLI walla 8.87E−03 2.38E−03 2.05E−02 4.03E−03 2.12E−02 4.04E−03 2.41E−02 2.27E−02
Small intestinea 4.52E−02 1.14E−02 3.01E−02 6.43E−03 3.03E−02 6.45E−03 3.54E−02 3.29E−02
Stomach walla 6.16E−03 2.06E−03 1.13E−02 1.95E−03 1.13E−02 1.97E−03 1.36E−02 1.25E−02
ULI walla 1.16E−02 3.35E−03 1.85E−02 3.78E−03 1.87E−02 3.77E−03 2.18E−02 2.03E−02
Heart walla 1.41E−02 3.12E−03 1.29E−02 1.83E−03 1.29E−02 1.83E−03 1.53E−02 1.41E−02
Kidneys 2.86E−02 7.27E−03 4.63E−02 1.14E−02 4.64E−02 1.13E−02 5.06E−02 4.85E−02
Liver 5.11E−02 1.31E−02 1.55E−02 3.64E−03 1.56E−02 3.61E−03 2.08E−02 1.82E−02
Lungs 3.01E−02 3.92E−03 1.55E−02 1.90E−03 1.55E−02 1.90E−03 1.93E−02 1.74E−02
Muscle 5.28E−03 3.72E−04 5.45E−03 3.87E−04 6.88E−03 6.17E−03
Ovaries N/A N/A N/A N/A 1.04E−02 9.28E−03
Pancreas 1.43E−03 7.16E−04 1.01E−02 3.70E−03 1.01E−02 3.68E−03 1.16E−02 1.09E−02
Red marrow 1.44E−02 2.81E−03 7.12E−03 3.84E−04 7.23E−03 3.79E−04 7.98E−03 7.61E−03
Osteogenic cells 8.57E−03 4.09E−04 8.64E−03 4.10E−04 1.17E−02 1.02E−02
Skin 4.36E−03 2.95E−04 4.43E−03 2.98E−04 5.60E−03 5.02E−03
Spleen 1.08E−02 7.26E−03 2.98E−02 1.85E−02 2.98E−02 1.85E−02 3.60E−02 3.28E−02
Testes 5.34E−03 3.77E−04 5.81E−03 4.43E−04 N/A 2.91E−03
Thymus 5.24E−03 3.33E−04 5.24E−03 3.33E−04 6.68E−03 5.96E−03
Thyroid 3.99E−04 2.10E−04 9.81E−03 4.29E−03 9.81E−03 4.29E−03 1.17E−02 1.08E−02
Urinary bladder walla 7.32E−02 1.51E−02 8.94E−02 1.73E−02 1.51E−01 2.99E−02 2.03E−01 1.77E−01
Uterus N/A N/A N/A N/A 1.20E−02 1.09E−02
Total body 8.77E−01 6.75E−02 6.49E−03 5.24E−04 6.68E−03 5.32E−04 8.46E−03 7.57E−03
ED ICRP60 1.57E−02 1.50E−03 1.93E−02 1.95E−03 2.43E−02 2.07E−02
ED ICRP103 1.65E−02 1.68E−03 1.98E−02 1.98E−03 2.25E−02 1.90E−02
aIrradiation from the organ content is accounted for residence time calculation
Table 3 Dosimetry assessment in choroid plexuses. The mass of the choroid plexuses was estimated assuming a cylindrical
geometry based on dimensions reported by Kuruoglu et al. for both male and female subjects [38]
Residence time (hours) Dose (mGy/MBq)
Average Min Max SD Male (2.76 g) Female (1.81 g)
Choroid plexuses 3.08E−04 1.35E−04 3.66E−04 9.88E−05 3.96E−02 5.66E−02
Gnesin et al. EJNMMI Research  (2017) 7:43 Page 6 of 10
Dose to kidneys is of paramount importance in case
of therapeutic applications, which might require the
use of specific protocols for kidney protection [42]. As
shown by preclinical studies, the radiotracer retention
in the kidneys increases with RGD multimerization
[43]. In accordance with that, we reported an absorbed
dose to kidneys of 46.4 μGy/MBq, which is nearly iden-
tical to that found by Doss and colleagues with a fluori-
nated monomeric RGD (i.e. 45 μGy/MBq) [34] and half
than that reported by Mittra et al. with a fluorinated di-
meric peptide (i.e. 97.6 μGy/MBq) [33] (see Table 4).
The doses to kidneys reported by others, though in the
same range of values, present differences that can be
explained by the different methods used. In particular,
Kim et al. found higher absorbed doses (71.61 μGy/
MBq) with a 68Ga-labelled monomeric RGD which can
be considered similar to the one used in the present
study; however, their methodology differs in the num-
ber of acquired time points (8 per patient) and in the fit
of the activity curve, which was obtained by applying a
trapezoid integration of acquired data assuming only
physical decay after the last time point (75 min post in-
jection) [36].
Beer et al. reported lower absorbed kidney doses
with the most commonly used RDG-based tracer, the
monomeric 18F-Galacto-RGD (29.52 μGy/MBq). How-
ever, they applied a partial organ segmentation on
three adjacent slices, which might result in quantita-
tive bias in presence of organ activity heterogeneity
[37]. Among the available dimeric peptides, 68Ga-
DOTA-E [cRGDfK]2 showed relatively low absorbed
doses; however, a comparison with the results of this
study is difficult because the number of exponential
components used in the fit and the mass of the organ
considered for dosimetry (patient specific or phan-
tom) were not specified [35].
In the present study, actual measurements were based
on a 30-min voiding interval and the EDs were esti-
mated according to both the ICRP60 and the ICRP103.
In addition, to allow the comparison with other similar
Fig. 4 Organ time-activity curves corrected for 68Ga physical decay. These data essentially show the biological organ kinetics of 68Ga-NODAGA-
RGDyK during the observation time. Colour bars represent the average percent of injected activity per gram of tissue (%IA/g) ± standard deviation
Table 4 Comparison of effective doses (ED) according to ICRP60 and absorbed doses to kidneys between available studies on RGD-
based radiopharmaceuticals assuming 1-h voiding cycle. Mean ± SD are reported
Radiopharmaceutical No. of patients ED ICRP60
(μSv/MBq)
Dose to kidneys
(μGy/MBq)
18F-Galacto-RGD (Beer et al.) [37] 18 18.68 ± 2.42 29.52 ± 11.95
18F-RGD-K5 (Doss et al.) [34] 4 15 ± 1 45 ± 10
18F-FPPRGD2a (Mittra et al.) [33] 5 39.6 ± 18.1 97.6 ± 50.2
68Ga-NOTA RGD (Kim et al.) [36] 10 24.98 ± 4.39 71.61 ± 28.38
68Ga-DOTA-E [cRGDfK]2a (Lopey-Rodriguez et al.) [35] 5 20.9 ± 5.1 53.8 ± 5.3b
68Ga-NODAGA-RGDyK (this study) 5b 19.3 ± 1.8b 46.4 ± 11.3b
aDimeric RDG radiopharmaceuticals
bValues are tabulated for male patients only
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studies, we also derived EDs for a 1-h voiding cycle
(Table 4).
According to the ICRP60, the EDs for a voiding inter-
val of 30 min were 15.7 μSv/MBq for male and 19.6 μSv/
MBq for female. Interestingly, these results confirm the
validity of the extrapolation we previously made from
mice biodistribution data to human dosimetry [24]. In
that previous study, we had estimated human EDs being
12 μSv/MBq for male and 16 μSv/MBq for female, re-
spectively. Of note, our extrapolation of EDs from mice
data showed a better agreement with human data than
the extrapolation from monkeys made by Doss and co-
workers (25 vs. 53% dose difference in our and in Doss’
study, respectively) [34].
By assuming a 1-h bladder voiding cycle, our ED re-
sults to be 20.7 μSv/MBq for the reference person, that
is 20% higher than with 30-min voiding cycle. This dose
estimation is comparable with the 19 μSv/MBq expected
form a 18F-FDG exam [44] and would result in an ED of
3.86 mSv after the injection of 200 MBq 68Ga-
NODAGA-RGDyK. It needs to be acknowledged that
the ED estimations for the reference person are poten-
tially biased by the absence of experimental data on fe-
male, that is an undesired effect of our dosimetry study
protocol, which was approved for the first five patients
only. Therefore, it was necessary to derive the female ED
from the residence times obtained in the male subjects
who exclusively composed our cohort.
Because of the limited number of patients, we did not
calculate doses for patient-specific organ volumes. Ra-
ther, we computed doses according to OLINDA/EXM
1.0 reference phantoms. This approach is reasonable in
the low dose range typical of radiopharmaceutical used
for diagnostic purposes in which the patient radioprotec-
tion is the main concern, considering the fact that ED is
a metric used for assessing stochastic risk in a popula-
tion. On the contrary, the use of patient-specific organ
masses would be crucial if a therapeutic approach was
considered.
A peculiarity of this work is the estimation of the
absorbed dose to the choroid plexuses, which are vascu-
lar structures localized in the brain ventricles, respon-
sible for the production of the cerebrospinal fluid [39].
Specific uptake by the choroid plexuses was already ob-
served with dimeric RGD peptides [33, 35], but, to the
best of our knowledge, no previous studies using mono-
meric tracers had reported such feature. Lopez-Rodriguez
and co-authors had measured the residence time in the
choroid plexuses but did not provide an estimation of the
absorbed dose, which was probably due to the difficulty of
defining an actual volume for this organ [35]. To estimate
the choroid plexuses mass, we referred to a previous mag-
netic resonance study [38]. We neglected the contribution
of the plexuses localized in the third and fourth ventricles,
as they clearly showed lower uptake than those localized
in the temporal and occipital horns of the lateral ventricles
(Fig. 2). Interestingly, choroid plexuses appear to be still in
the biological uptake phase at the end of the acquisition
time (Fig. 4). Although there are no specific dose con-
straints for the choroid plexuses in external beam ra-
diotherapy, in our opinion the relatively high doses
delivered to these structures would merit further consider-
ation, especially in case of therapeutic applications of
RGD peptides.
Conclusions
We have performed the first in-human dosimetry of
68Ga-NODAGA-RGDyK. This study indicates that a
200 MBq injection of 68Ga-NODAGA-RGDyK leads to
an effective dose in man of 3.86/3.92 mSv according to
the ICRP60/ICRP103 recommendation. For future thera-
peutic applications, specific attention should be directed
to delivered dose to kidneys and potentially also to the
choroid plexuses.
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